⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436290 | 0.79 | — | — | |
| SCHEMBL254616 | 0.79 | — | — | |
| SCHEMBL7029259 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL29446951 | 0.76 | — | — | |
| SCHEMBL2777562 | 0.73 | — | — | |
| SCHEMBL15074981 | 0.73 | — | — | |
| SCHEMBL7680338 | 0.73 | — | — | |
| SCHEMBL16566045 | 0.73 | — | — | |
| SCHEMBL1570079 | 0.73 | — | — | |
| SCHEMBL4536370 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013086373-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | claimed |
| EP-0233155-A1 | Aminoacyloxymethyl compounds | CIBA-GEIGY AG (CH) | 1987-08-19 | — | — | EP | claimed |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240175058-A1 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC., | 2024-05-30 | — | — | US | disclosed |
| US-20240130969-A1 | LIPID NANOPARTICLES AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-04-25 | — | — | US | disclosed |
| EP-4351651-A1 | LIPID NANOPARTICLES AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240084274-A1 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11866728-B2 | Engineered retrons and methods of use | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230235365-A1 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023141602-A2 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013086373-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-0036521-A1 | Preparation of 2-imidazolines | BASF Aktiengesellschaft (DE) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036519-A1 | Process for the preparation of imidazole | BASF Aktiengesellschaft (DE) | 1981-09-30 | — | — | EP | disclosed |
| EP-0025191-A1 | Process for the preparation of imidazoles | BASF Aktiengesellschaft (DE) | 1981-03-18 | — | — | EP | disclosed |